ABBV-438

A Phase 1, First-in-Human, Open Label Study Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ABBV-438 in Adult Subjects With Relapsed or Refractory Multiple Myeloma

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
127 patients (estimated)
Tags
Antibody Drug Conjugate (ADC)
Trial Type
Treatment
Last Update
SparkCures ID
2244
NCT Identifier
NCT07409246

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.